Crawley CCG LCS Dec 15 Final
|
|
- Abraham Welch
- 6 years ago
- Views:
Transcription
1 Crawley CCG LCS Dec 15 Final Crawley CCG Service Proposal for the inclusion of administration and monitoring of Denosumab 60mg Injection (Prolia )in GP Practices under a Locally Commissioned Service February 2016
2 Executive Summary Denosumab (Prolia ), a drug for osteoporosis, is administered by six-monthly injection and requires monitoring of calcium levels. GP Practices in Brighton and Hove CCG and High Weald Lewes and Havens CCG are paid to administer and monitor Denosumab under their agreed LCS s. The possibility of patients receiving the same service from their GP practice was raised at the Crawley CCG Locality Prescribing Committee where some patients attend hospital to receive this treatment. The current position is different in Crawley CCG where 73% of Denosumab (based on epact figures (April 14-Nov15) is prescribed and administered by the Fracture Liaison Service*/Bridge Medical Centre. This document outlines the options available for administering and monitoring Denosumab in GP practices in Crawley CCG and their potential financial impact. This proposal has been agreed in principle at the Crawley CCG Executive Committee. *Note: The CCG has now received notice that this service will no longer be available from 31 st March 2016 The Primary Care Commissioning Committee is asked to review the proposal and to make a decision on appropriate payment for GP practices to provide this service. Background Information Denosumab (Prolia, Amgen) is a monoclonal antibody that reduces osteoclast activity, and so reduces bone breakdown. Denosumab has a UK marketing authorisation for the treatment of osteoporosis in postmenopausal women and men at increased risk of fractures. The summary of product characteristics states that in postmenopausal women that Denosumab significantly reduces the risk of vertebral, non-vertebral and hip fractures. Denosumab is administered as a single subcutaneous injection into the thigh, abdomen or back of the arm. The recommended dosage is 60 mg once every 6 months In October 2010 NICE published NICE technology appraisal guidance [TA204] for Denosumab for the prevention of osteoporotic fractures in postmenopausal women. TA204 recommends Denosumab as a treatment option for the primary prevention of osteoporotic fragility fractures in postmenopausal women at increased risk of fractures, who comply with particular combinations of bone mineral density measurement, age and independent risk factors for fracture, as indicated in the full NICE guidance (available at
3 NICE TA 204 also recommends Denosumab as a treatment option for postmenopausal women for secondary prevention of osteoporosis. For both primary and secondary prevention Denosumab is only recommended by NICE for those women who are unable to comply with the special instructions for administering alendronate and either risedronate or etidronate, (all oral therapies) or have an intolerance of, or a contraindication to, those treatments. NICE TA 204 means that Denosumab must be available in our CCG as a treatment option to patients fulfilling NICE criteria Since the publication of the NICE TA the CCG has determined the place of Denosumab in the osteoporosis prevention and treatment pathway agreeing the recommendation of the PCN in the CPMAP meeting in June 2014 to make it GREEN on the CCG Formulary Traffic Light System (Suitable for non-specialist initiation) The Case for Change Since the introduction of Denosumab for osteoporosis the number of patients receiving Denosumab as a six-monthly injection has increased dramatically. In Crawley CCG a GREEN formulary designation means practices are able to initiate Denosumab in appropriate patients, without the need for referral. In practice around 70% Crawley patients have been receiving Denosumab via a commissioned Fracture Liaison Service* provided by Bridge Medical Centre/Fracture Liaison Nurse. The cost of the Denosumab for these patients has been born by Bridge Practices prescribing budget. The CCG has now received notice that this service will no longer be available from 31st March 2016 There is no vehicle by which Crawley practices can be reimbursed for the time taken to prescribe, initiate, administer and monitor denusomab patients within their surgeries although they may claim under GMS for personally administered items. As the number of patients receiving 6 monthly injections has increased (from 104 injections prescribed in 2012/13 to 215 prescribed items in 2014/15) so the impact for GP practices and/or the Fracture Liaison Service has increased. Denosumab must be administered by subcutaneous injection. In addition prior to each injection the patient must attend for a blood test to check for hypocalcaemia as clinical monitoring of calcium levels is recommended before each dose and, in patients predisposed to hypocalcaemia within two weeks after the initial dose.
4 This proposal is also being put forward by Crawley CCG following a Prescribing Meeting where concern was expressed about the additional work entailed for practices, especially practice nurses, and the resulting impact on other practice services. It was requested therefore that Denosumab for osteoporosis is added to the current drug monitoring LCS. Period Name Prescriber Name BNF Name Total Items Total Act Cost Financial 2012/2013 Financial 2013/2014 Financial 2014/2015 Financial 2015/16 (Year to date April 14 to Nov 15) CRAWLEY CCG Denosumab Inj 60mg/1ml pfs , CRAWLEY CCG Denosumab Inj 60mg/1ml pfs , CRAWLEY CCG Denosumab Inj 60mg/1ml pfs , CRAWLEY CCG Denosumab Inj 60mg/1ml pfs , Figures from EPACT Options 1. Do nothing 2. Commission additional capacity from the Secondary Care or Fracture Liaison Service* 3. Include Denosumab for osteoporosis in existing LCS for Shared Care Drug Monitoring cost per patient, claimed quarterly (Equivalent p.a.) - Brighton and Hove CCG have included Denosumab in their Shared Care Drug Monitoring LCS 4. Include Denosumab under the Minor Surgery LCS with the following options:- a) half unit per activity ( 15.15) This option already includes administration of hormonal implants by injection e.g. Prostap, Zoladex which require no blood monitoring b) one whole unit per activity ( 30.30) HWLH CCG includes Denosumab in the same category as Prostap etc ( per injection).
5 Option 1 Do Nothing Practices could refer all patients requiring Denosumab injections back to the Secondary Care or Fracture Liaison Service* for blood tests and administration of injections resulting in increased work for this service giving routine injections. Risk of less future practice engagement in taking up shared care and/or treating complex patients in primary care Option 2 Commission additional capacity for FLS* The Fracture Liaison Service* or Secondary Care would require additional resources and clinic time to provide this routine service. Patients would need to travel further from home to receive the service. *Note The CCG has now received notice that the Fracture Liaison Service will no longer be available from 31 st March 2016 Option 3 Add Denosumab to the Drug Monitoring LCS Denosumab has been designated GREEN on the CCG Formulary by the CCG. All drugs on the current Drug Monitoring LCS are currently designated at least AMBER and are initiated in secondary care with prescribing and monitoring being undertaken by the GP under an agreed shared care agreement. If Denosumab were included under this LCS this would be an exception since the GREEN designation means patient care can be managed wholly in primary care. Estimated Annual Cost for Crawley CCG if Denosumab is added to the drug monitoring LCS = 9,492 based on 107 patients at patients p.a. *(213/2 six monthly injections extrapolated from April-14-Nov-15 epact figures) Option 4 Include Denosumab under the Minor Surgery LCS The current Minor Surgery LCS already includes hormonal implants by injection e.g. Zoladex, Prostap paid at half unit per quarter These require no specific blood monitoring. These drugs are designated BLUE or GREEN on the Formulary and are usually initiated by a specialist. a) Half Unit per activity Estimated Cost in Crawley CCG if Denosumab is added to the Minor Surgery LCS = 3,242 p.a. based on 107* patients at ( per administration x 2). b) Whole Unit per activity
6 Estimated Cost in Crawley CCG if Denosumab is added to the Minor Surgery LCS as a whole unit = 6,484 p.a. based on 107* patients at ( per administration x 2). *(213/2 six monthly injections extrapolated from April-14-Nov-15 epact figures) Definition from current Minor Surgery LCS: Half Unit could be performed by a practice nurse e.g Hormonal implants by injection, Suture removal, Ear syringing, vault smears Whole Unit could be performed by practice nurse more usually doctor e.g. Repair of laceration by glue, steroid injection of keloid, removal of nasal packaging, drainage of subungual haematoma Benefits of Change The proposed addition of Denosumab to an LCS will:- Reduce the number of referrals to the Fracture Liaison Service* or Secondary Care for initiation and continued administration of Denosumab freeing capacity for this service for assessment and diagnosis. Enable more patients to be treated closer to home at their own GP surgeries. Provide funding for additional practice nurse time to ensure Denosumab is correctly administered and monitored in GP Practices. Additional experience could mean that patients fulfilling NICE TA 204 criteria could also be commenced on Denosumab without referral to Secondary Care or the Fracture Liaison Service. Risks of having an LCS: If uptake of the LCS is not consistent across the CCG there could be a risk of inequity in treatment and care of patients with osteoporosis. This risk could be mitigated by offering practices the opportunity to provide the service on behalf of another practice or a group of practices Risks of not having an LCS: Practices could refer all patients requiring Denosumab injections back to Secondary care or the Fracture Liaison Service* for blood tests and administration of injections resulting in increased work for this service giving routine injections. Risk of less future practice engagement in taking up shared care and/or treating complex patients in primary care
7 Summary of Proposal Summary Proposal Drug Indication Dosage and monitoring To determine how Denosumab (Prolia ), a six-monthly injection for patients with osteoporosis fulfilling TA204 will be given in primary care in Crawley CCG Addition of Denosumab (Prolia ) to either Shared Care Drug Monitoring LCS or Minor Surgery LCS or to continue existing arrangement where approx.70% of patients are treated and monitored by the Fracture Liaison Service* or Secondary Care. Denosumab (Prolia ) 60mg pre-filled syringe for subcutaneous injection (NB There is another Denosumab (Xgeva ) licensed for bone metastases from breast cancer. This proposal does not include this product) Primary and secondary prevention of osteoporosis in women intolerant or unable to comply with oral bisphosphonates fulfilling NICE TA204 Six monthly sub-cutaneous injection Blood test for hypocalcaemia before each dose and, in patients predisposed to hypocalcaemia within two weeks after the initial dose. Formulary status Green Reason for request Advantages of addition to LCS Monitoring of LCS CCG member practices have requested inclusion in the current LCS scheme because of increased use of this drug in primary care requiring administration by injection and blood test monitoring Patients may be treated at their own surgeries closer to home. Removal of administration of routine injections will mean Fracture Liaison Service* or Secondary Care will have additional capacity. As individual schemes
8 Potential Costs Drug Monitoring LCS per patient per quarter (Equivalent p.a.) Estimated annual cost 9,492 based on an estimated 107 patients Minor Surgery LCS Half-Unit per administration (Equivalent to p.a.) Estimated annual cost 3,242 based on an estimated 107 patients Whole Unit per administration (Equivalent to p.a.) Estimated annual cost 6,484 based on an estimated 107 patients Fracture Liaison Service* No costs specific to administration of Denosumab in existing service identified. *Note: The CCG has now received notice that this service will no longer be available from 31 st March 2016
Oxford University Hospitals NHS Trust, Oxfordshire Primary Care Trust, Oxfordshire Clinical Commissioning Group and Oxford Health NHS Trust
Oxford University Hospitals NHS Trust, Oxfordshire Primary Care Trust, Oxfordshire Clinical Commissioning Group and Oxford Health NHS Trust Shared Care Protocol and Information for GPs TERIPARATIDE, rhpth
More informationProvision of Near-Patient Testing Service. Service Level Agreement Background. 2. Financial Details
Provision of Near-Patient Testing Service Service Level Agreement 2016-2019 Contents: 1. Financial Details 2. Service Aims 3. Criteria 4. Ongoing Measurement & Evaluation 5. Accreditation 1. Background
More informationStandard Operating Procedure for the administration of Red and Amber Drugs within Integrated Community Care Services
Standard Operating Procedure for the administration of Red and Amber Drugs within Integrated Community Care Services Reference No: Version: 1 Author: Emma Baggaley First Issued On: 1 st March 2018 Latest
More informationOxfordshire Primary Care Commissioning Committee. Date of Meeting: 3 January 2017 Paper No: 9
Oxfordshire Clinical Commissioning Group Oxfordshire Primary Care Commissioning Committee Date of Meeting: 3 January 2017 Paper No: 9 Title of Presentation: OCCG Primary Care Locally Commissioned Services
More informationPatient Group Direction for Aspirin 300mg Version: 02 Start Date: 1 st October 2017 Expiry Date: 30 th September 2019
THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS: CLINICAL COMMISSIONING GROUP: Doncaster CCG, Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire
More informationInitiation of Warfarin for patients not registered with Provider Practice
Initiation of Warfarin for patients not registered with Provider Practice 2017-18 1. Purpose of Agreement This Agreement outlines the service to be provided by the Provider, called Initiation of Warfarin
More informationLocally Commissioned Services report
Locally Commissioned Services report Locally Commissioned Services are services that have been agreed locally between the CCG and our practices to meet the identified needs and priorities of our population.
More informationWebEx: The Golden Ticket A primary care dementia model Monday 19 March 2018, 15:00-16:00
WebEx: The Golden Ticket A primary care dementia model Monday 19 March 2018, 15:00-16:00 Julie Miller Focus on Dementia ihub, Healthcare Improvement Scotland WebEx agenda Time Item Lead 15:00 Welcome Julie
More informationSERVICE SPECIFICATION FOR THE PROVISION OF LONG-ACTING REVERSIBLE CONTRACEPTION SUB-DERMAL CONTRACEPTIVE IMPLANTS IN BOURNEMOUTH, DORSET AND POOLE
Revised for: 1 April 2015 Updated: 16 April 2015 Appendix 2.2 SERVICE SPECIFICATION FOR THE PROVISION OF LONG-ACTING REVERSIBLE CONTRACEPTION SUB-DERMAL CONTRACEPTIVE IMPLANTS IN BOURNEMOUTH, DORSET AND
More informationEastbourne, Hailsham and Seaford CCG Item Number: Formal Governing Body meeting Date of meeting: 13 November /13
Eastbourne, Hailsham and Seaford CCG Item Number: Formal Governing Body meeting Date of meeting: 13 November 2013 219/13 Title of report: Dementia: Memory Assessment Service update since October 2013.
More informationLinda Cutter / Dr Charles Heatley. GP Practices and Community Pharmacies
Schedule 2 Part A Service Specification Service Specification No. 04 Service Anti-coagulation Monitoring Levels 3, 4 & 5 Commissioner Lead Provider Lead Linda Cutter / Dr Charles Heatley GP Practices and
More informationSussex and East Surrey STP narrative
Sussex and East Surrey STP narrative What is the STP? The Sussex and East Surrey Sustainability and Transformation Partnership (STP) outlines how the NHS and social care will work together to improve and
More informationUnlicensed Medicines Policy
Unlicensed Medicines Policy This procedural document supersedes: PAT/MM 4 v.3 Policy and Procedure for the Use of Unlicensed Medicines Did you print this document yourself? The Trust discourages the retention
More informationBreast Reduction. Individual Funding Request (IFR) Policy
Breast Reduction Individual Funding Request (IFR) Policy Date of Adoption: 13 July 2016 Version: 1617 v2 Document Control Title of document Breast Reduction Individual Funding Request (IFR) Policy Authors
More informationDerby Hospitals NHS Foundation Trust. Drug Assessment
Drug Assessment for Preparation and Administration of Oral, Enteral, Ophthalmic, Topical, PR, PV, Inhaled, Subcutaneous and Intramuscular Medicines to Patients (N.B. The preparation and administration
More informationPRESCRIBING SUPPORT TECHNICIAN:
PRESCRIBING SUPPORT TEAM AUDIT: CARDURA XL (Updated Sept 09) DATE OF AUTHORISATION: AUTHORISING GP: PRESCRIBING SUPPORT TECHNICIAN: SUMMARY Cardura XL is a once daily, extended release preparation of doxazosin
More informationHome therapy with Immunoglobulin
Home therapy with Immunoglobulin Turnberg Building Immunology Department 0161 206 5576 All Rights Reserved 2017. Document for issue as handout. You have been diagnosed with antibody deficiency and you
More informationPatient Group Direction for ACICLOVIR (Version 02) Valid From 1 October September 2019
Version Control This PGD has been agreed by the following organisations FCMS PDS Medical Doncaster CCG Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire CCGs Change history
More informationGG&C PGD ref no: 2011/841 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT
GG&C PGD ref no: 2011/841 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Inclusion criteria: Exclusion criteria:
More informationNHS GREATER GLASGOW AND CLYDE POLICIES RELATING TO THE MANAGEMENT OF MEDICINES SECTION 9.1: UNLICENSED MEDICINES POLICY (ACUTE DIVISION)
SECTION 9.1: UNLICENSED MEDICINES POLICY (ACUTE DIVISION) CONTENTS POLICY SUMMARY... 2 1. SCOPE... 4 2. AIM... 4 3. BACKGROUND... 4 4. POLICY STATEMENTS... 5 4.1. GENERAL STATEMENTS... 5 4.2 UNLICENSED
More informationMMPR034 MEDICINES RECONCILIATION ON ADMISSION TO HOSPITAL PROTOCOL
MMPR034 MEDICINES RECONCILIATION ON ADMISSION TO HOSPITAL PROTOCOL 1 Table of Contents Why we need this Protocol...3 What the Protocol is trying to do...3 Which stakeholders have been involved in the creation
More informationAnti-Coagulation Monitoring (warfarin, acenocoumarol, phenindione) Primary Care Service (PCS:01) NHS Standard Contract Service Profile Pack ( )
Anti-Coagulation Monitoring (warfarin, acenocoumarol, phenindione) Primary Care Service (PCS:01) This pack contains: Standard Contract Service Profile Pack () 1. Service Specification: (to be inserted
More informationPATIENT GROUP DIRECTION (PGD) FOR THE
PGD 1 PATIENT GROUP DIRECTION (PGD) FOR THE ADMINISTRATION OF DARBEPOETIN ALFA BY RENAL NURSES TO PATIENTS ATTENDING THE RENAL UNIT, MONKLANDS HOSPITAL, FOR HAEMODIALYSIS /HAEMODIAFILTRATION This document
More informationNHS Fife. Patient Group Direction for Named Community Pharmacists to Supply
Patient Group Direction for Named Community Pharmacists to Supply Senna tablets 7.5mg or Senna syrup 7.5mg/5ml (Total sennosides calculated as sennoside B) For patients aged 16 years and older prescribed
More informationPrescribing & Medicines: Reimbursement and remuneration paid to dispensing contractors
Publication Report Prescribing & Medicines: Reimbursement and remuneration paid to dispensing contractors Calendar and financial years 2007-2012 Publication date 25 September 2012 A National Statistics
More informationDermabrasion for Acne Scarring
Dermabrasion for Acne Scarring Individual Funding Request Policy DATE ADOPTED: 09 December 2015 Version: 1516.v1.1 SCW CSU IFR Dermabrasion for Acne Scarring Policy for SCCG v1.2 Page 1 Document Control
More informationProcess and methods Published: 23 January 2017 nice.org.uk/process/pmg31
Evidence summaries: process guide Process and methods Published: 23 January 2017 nice.org.uk/process/pmg31 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationADMINISTRATION OF INSULIN IN THE COMMUNITY BY SUPPORT WORKERS
Title Purpose ADMINISTRATION OF INSULIN IN THE COMMUNITY BY SUPPORT WORKERS This guideline is to assist: Service Providers (organisations and individuals), Participants, stakeholders and funders regarding
More informationPrimary Care/Community Based Service Palliative Care (Just in Case Medicines) Fylde and Wyre CCG Pete Smith. Community Pharmacy
Service Specification No. 1. Service Commissioner Lead Provider Lead Primary Care/Community Based Service Palliative Care (Just in Case Medicines) Fylde and Wyre CCG Pete Smith Community Pharmacy Period
More informationCommissioning Medicines for Children in Specialised Services. Reference: NHS England: /P
Commissioning Medicines for Children in Specialised Services Reference: NHS England: 170001/P 1 NHS England INFORMATION READER BOX Directorate Medical Operations and Information Specialised Commissioning
More informationCancer Drugs Fund. Managed Access Agreement. Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
Cancer Drugs Fund Managed Access Agreement Daratumumab monotherapy for treating relapsed and refractory multiple myeloma NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Cancer Drugs Fund Data Collection
More informationHow Pharmacies are supporting the move from Secondary to Primary Care. Peter Bainbridge, Director of Pharmacy,
How Pharmacies are supporting the move from Secondary to Primary Care Peter Bainbridge, Director of Pharmacy, Alliance Boots Present in over 25 countries Over 116,000 employees 3,330 Health and Beauty
More informationPrescribing Policy between Nottinghamshire Commissioning Organisations and local providers of NHS Services
Prescribing Policy between Nottinghamshire Commissioning Organisations and local providers of NHS Services Document Purpose Version 2.2 To detail the specific contractual issues associated with prescribing
More informationUpdate Report to Clinical Members. Quarter 3; what have we done so far
Update Report to Clinical Members Quarter 3; what have we done so far Introduction: Dr Charlotte Canniff, Clinical Chair Following our Council of Members meeting in October we heard and recognised a clear
More informationPrime Contractor Model King s Fund Nick Boyle Consultant Surgeon 27 March 2014
Prime Contractor Model King s Fund Nick Boyle Consultant Surgeon 27 March 2014 Current Referral Route options - Information 1. Horizon Health Choices Horizon Musculoskeletal Triage & Treatment Chronic
More informationEMERGENCY CARE DISCHARGE SUMMARY
EMERGENCY CARE DISCHARGE SUMMARY IMPLEMENTATION GUIDANCE JUNE 2017 Guidance for implementation This section sets out issues identified during the project which relate to implementation of the headings.
More informationBest Practice Guidance for Supplementary Prescribing by Nurses Within the HPSS in Northern Ireland. patient CMP
Best Practice Guidance for Supplementary Prescribing by Nurses Within the HPSS in Northern Ireland patient CMP nurse doctor For further information relating to Nurse Prescribing please contact the Nurse
More informationTitle: Replacement of the Commissioning Advisory Forum Agenda Item: 9
Meeting of Bristol Clinical Commissioning Group To be held on Tuesday, 2 July 2013 commencing at 1.30 pm in the BAWA Centre Title: Replacement of the Commissioning Advisory Forum Agenda Item: 9 1 Purpose
More informationNON-MEDICAL PRESCRIBING POLICY
NON-MEDICAL PRESCRIBING POLICY PROCEDURE NUMBER Clinical.186 PROCEDURE VERSION 2 (Review). RATIFYING COMMITTEE Policy and Professional Practice Forum DATE RATIFIED 20 October 2015 DATE OF EQUALITY & September
More informationPrinciples of Shared Care Protocols
Principles of Shared Care Protocols 1 Robust shared care arrangements facilitate the safe transition of medicines for use in a specified condition between secondary and primary care clinicians with the
More informationMartina Khundakar - Senior Clinical Pharmacist Teresa Barnes - Lead Clinical Pharmacist - Specialist Care. Timothy Donaldson, Trust Chief Pharmacist
Policy on Pharmacological Therapies Practice Guidance Note The use of Oral Anti-Cancer Medicines and Oral Methotrexate within - V03 V03 - Issued Issue 1 Dec 15 Planned review December 2018 PPT-PGN 09 Part
More informationRegister No: Status: Public
ADMINISTRATION OF VITAMIN K FOR NEONATES CLINICAL GUIDELINES Register No: 08095 Status: Public Developed in response to: Contributes to CQC Outcome 11,12 Intrapartum NICE Guidelines CNST Requirement Consulted
More informationPrescribing & Medicines: Reimbursement and remuneration paid to dispensing contractors
Publication Report Prescribing & Medicines: Reimbursement and remuneration paid to dispensing contractors Quarter Three of Financial Year 2015/16 Publication date 22 March 2016 A National Statistics Publication
More informationANTI-COAGULATION MONITORING
ANTI-COAGULATION MONITORING 2016-17 a) Purpose of Agreement This Agreement outlines the service to be provided by the Provider, called an Anti-coagulation monitoring service. b) Duration of Agreement This
More informationSwitch protocol: Brands to generic equivalent
Switch protocol: Brands to generic equivalent Applies to HaRD CCG employed Pharmacists and Medicines Optimisation Technicians. These protocols are produced by the NY&AWC MM team hosted by HaRD CCG for
More informationTop tips for prescribing in palliative care. Dr Stephanie Lippett
Top tips for prescribing in palliative care Dr Stephanie Lippett contents Tips Pain management Anticipatory prescribing DNACPR 3 things that primary care can do to improve things for patients/themselves
More informationThis SLA covers an enhanced service for care homes for older people and not any other care category of home.
Care Homes for Older People Service Level Agreement 2016-2019 All practices are expected to provide essential and those additional services they are contracted to provide to all their patients. This service
More informationNON-MEDICAL PRESCRIBING POLICY
NON-MEDICAL PRESCRIBING POLICY To be read in conjunction with the Medicines Policy, Controlled Drug Policy and the FP10 Prescribing Forms Policy Version: 5 Date of issue: August 2017 Review date: August
More informationSCHEDULE 2 THE SERVICES
SCHEDULE 2 THE SERVICES A. Service Specifications Service Specification. 001 Service Commissioner Lead Contracting Lead Provider Lead Period Teledermoscopy Service Dr Nicholas Rayner and Dr Andrew Yager
More informationImprovement and Assessment Framework Q1 performance and six clinical priority areas
Governing Body 30 th September 2016 Improvement and Assessment Framework Q1 performance and six clinical priority areas Agenda item 16 Paper 10 Summariser: Authors and contributors: Executive Lead(s):
More informationMEDICINES STANDARD B3: WORKING WITH THE PHARMACEUTICAL INDUSTRY
MEDICINES STANDARD B3: WORKING WITH THE PHARMACEUTICAL INDUSTRY NHS employees and contractors link with the pharmaceutical industry in a number of ways, as a source of information, through the receipt
More informationBEST PRACTICE GUIDANCE-SUPPLEMENTARY PRESCRIBING
BEST PRACTICE GUIDANCE-SUPPLEMENTARY PRESCRIBING NON MEDICAL PRESCRIBING ADVISOR IMPLEMENTATION DATE: MAY 2009 REVIEW DATE: MAY 2010 Supplementary Prescribing The working definition of supplementary prescribing
More informationabcdefghijklmnopqrstu
NHS Circular: PCA(M)(2011)5 Health and Social Care Integration Directorate Primary Care Division abcdefghijklmnopqrstu Dear Colleague THE PRIMARY MEDICAL SERVICES (DIRECTED ENHANCED SERVICES) (SCOTLAND)
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
Managing neutropenic sepsis in secondary and tertiary care bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly
More informationOCCG SERVICE SPECIFICATION (2017/18) PRIMARY CARE SERVICE FOR THE PROVISION OF ARRHYTHMIA DIAGNOSTIC SERVICES
OCCG SERVICE SPECIFICATION (2017/18) PRIMARY CARE SERVICE FOR THE PROVISION OF ARRHYTHMIA DIAGNOSTIC SERVICES 1. Introduction This service covers the use of cardiac event monitors (CEMs) for the diagnosis
More informationNHS England London Southside 4th Floor 105 Victoria Street London SW1E 6QT. 24 th July Dear Daniel, Fiona and Louise. Re: CCG Annual Assurance
NHS England London Southside 4th Floor 105 Victoria Street London SW1E 6QT 24 th July 2014 Dear Daniel, Fiona and Louise Re: CCG Annual Assurance Many thanks for meeting with us on 6 th June 2014 to discuss
More informationService specification for Age Related Macular Degeneration Referral Service. Reference: - 201
Service specification for Age Related Macular Degeneration Referral Service Reference: - 201 Document Version Control Version Reason Date Author 1.0 Inherited from PCT 1st April 2013 unknown 1.1 Updating
More informationWest Wandsworth Locality Update - July 2014
Attach 5 West Wandsworth Locality Update - July 2014 1) Introduction The West Wandsworth Locality covers the areas of Roehampton and Putney, and the nine practices that lie in these areas. The 2013 GP
More informationabcdefghijklmnopqrstu
Healthcare Policy and Strategy Directorate Quality Division Dear Colleague INTRODUCTION AND AVAILABILITY OF NEWLY LICENSED MEDICINES IN THE NHS IN SCOTLAND Dear Colleague This guidance sets out the policy
More informationNovember NHS Rushcliffe CCG Assurance Framework
November 2015 NHS Rushcliffe CCG Assurance Framework ASSURANCE FRAMEWORK SUMMARY No. Lead & Sub Committee Date placed on Assurance Framework narrative Residual rating score L I rating in 19 March 2015
More informationTitle Protocol for the Management of Chest Wall Injuries (over 12 years of age) in MIU s and WIC s.
Document Control Title Protocol for the Management of Chest Wall Injuries (over 12 years of age) in MIU s and WIC s. Author Author s job title Professional Lead, Minor Injuries Unit Directorate Department
More informationNational Care of the Dying Audit Hospitals (NCDAH) Round 3
National Care of the Dying Audit Hospitals (NCDAH) Round 3 This audit is being led by the Marie Curie Palliative Care Institute Liverpool in collaboration with the Royal College of Physicians, and is supported
More informationNAME: DATE: MARGARETVILLE HOSPITAL PHYSICIAN ASSITANT/NURSE PRACTITIONER ED CLINICAL PRIVILEGES
SUPERVISING PHYSICIAN(s): MARGARETVILLE HOSPITAL PHYSICIAN ASSITANT/NURSE PRACTITIONER ED CLINICAL PRIVILEGES The following privileges are required to practice in the Emergency Room of Margaretville Hospital:
More informationDocument Details. notification of entry onto webpage
Document Details Title Patient Group Direction (PGD) Administration of sodium chloride 0.9% injection by registered professionals Trust Ref No 1987-38096 Local Ref (optional) Main points the document As
More information2. The main aims of the implementation facilitator role can be captured by the following objectives:
NICE in Northern Ireland Implementation Facilitator Engagement Activities 2013/14 Executive Summary 1. From 1 October 2012, NICE was able to secure funding, after negotiations with the Department of Health,
More informationAnaphylactic Reaction Emergency Treatment Reference Number:
This is an official Northern Trust policy and should not be edited in any way Anaphylactic Reaction Emergency Treatment Reference Number: NHSCT/12/551 Target audience: Nursing Staff Groups included are:
More information5.3: POLICY FOR THE MANAGEMENT OF REQUESTS FOR MEDICINES VIA PEER APPROVED CLINICAL SYSTEM (PACS) TIER 2
NHS GREATER GLASGOW AND CLYDE POLICIES RELATING TO THE MANAGEMENT OF MEDICINES SECTION 5: NON-FORMULARY PROCESSES 5.3: POLICY FOR THE MANAGEMENT OF REQUESTS FOR MEDICINES VIA PEER APPROVED CLINICAL SYSTEM
More informationPatient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM DENOSUMAB. Patient s first names.
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM DENOSUMAB Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital St. Thomas
More informationReduce general practice consultations and prescriptions for minor conditions suitable for self-care
Reduce general practice consultations and prescriptions for minor conditions suitable for self-care To be read in conjunction with the following CCG policies: Joint Formulary C03 Low Priority Procedures
More informationPATIENT GROUP DIRECTION (PGD) FOR Metronidazole 400mg Tablets
Antibiotic Oral (tablet/capsule/suspension) PATIENT GROUP DIRECTION (PGD) FOR YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Caution: This
More informationIron infusions in the community
i NOTIFICATION Iron infusions in the community 11 September 2017 What we re doing Eligible people will now be able to receive ferric carboxymaltose iron infusions in some general practitioners clinics
More informationBoard of Directors Meeting Report 5 December Agenda item 90/17
Board of Directors Meeting Report 5 December 2017 Agenda item 90/17 Title Position Statement - Ophthalmology Sponsoring Director Author(s) Purpose Executive Summary Yvonne Blucher Jane Mulreany Margaret-Ann
More informationCommissioning Policy
Commissioning Policy Consultant to Consultant Referrals Version 6.0 December 2017 Name of Responsible Board / Committee for Ratification: North Staffordshire CCG Stoke on Trent CCG Date Issued: November
More informationJennifer Riley, Senior Commissioning Manager. Barry Silvert, Clinical Director Commissioning
NHS BOLTON CLINICAL COMMISSIONING GROUP Public Board Meeting AGENDA ITEM NO: 7 Date of Meeting: 24 th June TITLE OF REPORT: AUTHOR: PRESENTED BY: PURPOSE OF PAPER: (Linking to Strategic Objectives) Pain
More informationRadiology CPG Annual Report for Quality, Safety and Experience Sub-Committee- April 2015
Radiology CPG Annual Report for Quality, Safety and Experience Sub-Committee- April 2015 1. Purpose of report To provide assurance to the QSE sub-committee of the Radiology CPG s commitment to quality,
More informationPROPOSAL TO UPDATE NEAR PATIENT TESTING ENHANCED SERVICE
PROPOSAL TO UPDATE NEAR PATIENT TESTING ENHANCED SERVICE 1.0 ACTION BY AWMSG: The All Wales Medicines Strategy Group (AWMSG) meeting held on 15 th December 2010 considered and approved the recommendations
More informationJOB DESCRIPTION. Consultant in Palliative Medicine GENERAL
JOB DESCRIPTION JOB TITLE DEPARTMENT REPORTS TO ACCOUNTABLE TO Consultant in Palliative Medicine Medical Team Lead Consultant Director of Patient Care GENERAL ellenor is a specialist palliative care provider
More informationCoastal West Sussex Interface Prescribing Policy
Coastal West Sussex Interface Prescribing Policy Agreement between Commissioners: Coastal West Sussex CCG And Providers: Western Sussex NHS Foundation Trust (WSfT) Sussex Community NHS Trust (SCT) Sussex
More informationThe New NHS What does this mean for the patient pathway?
The New NHS What does this mean for the patient pathway? Jesme Fox In general, Patients haven t noticed yet! Much anxiety / suspicion about quality of NHS care (Mid Staffs etc...) Focus should be on clinical
More informationWorkflow. Optimisation. hereweare.org.uk. hereweare.org.uk
Workflow Optimisation Dr. Paul Deffley & Jaivir Pall Clinical Lead & Commercial Lead About Here Not-for-profit social enterprise Membership organisation (our members are local GPs, Practice Managers, Practice
More informationReview of Local Enhanced Services
Review of Local Enhanced Services 1. Background and context 1.1 CCGs are required to prepare for the phasing out of LESs by April 2014 by reviewing the existing LES portfolio and developing commissioning
More informationNHS DORSET CLINICAL COMMISSIONING GROUP GOVERNING BODY MEETING A&E DELIVERY AND URGENT CARE BOARD UPDATE
NHS DORSET CLINICAL COMMISSIONING GROUP GOVERNING BODY MEETING A&E DELIVERY AND URGENT CARE BOARD UPDATE Date of the meeting 17/05/2017 Author Sponsoring GB member Purpose of Report Recommendation Stakeholder
More informationReview of Terms of Reference of Quality Assurance Committee
Review of Terms of Reference of Quality Assurance Committee Governing Body meeting 3 May 2018 H Author(s) Sponsor Director Purpose of Paper Sue Laing, Corporate Services Risk and Governance Manager Mandy
More informationConsultant to Consultant Referral Policy
Consultant to Consultant Referral Policy Version Author Date Comments Approved by No V1.0 Mel Sims 19 January 2017 To be APPROVED Governing Body Reader information Reference Document purpose COM002 This
More informationCCG Policy for Working with the Pharmaceutical Industry
CCG Policy for Working with the Pharmaceutical Industry 1. Introduction Medicines are the most frequently and widely used NHS treatment and account for over 12% of NHS expenditure. The Pharmaceutical Industry
More informationPolicy for Anticipatory Prescribing and Just in Case Bags
Policy for Anticipatory Prescribing and Just in Case Bags This policy was developed by Milton Keynes End of Life Care Medicine Group and has been adopted by all partner organisations (MK Clinical Commissioning
More informationExpiry Date: January 2009 Template Version: Page 1 of 7
YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Inclusion criteria: Exclusion criteria: Cautions/Need for
More informationSouth East London Interface Prescribing Policy including the NHS and Private Interface Prescribing Guide
South East London Interface Prescribing Policy including the NHS and Private Interface Prescribing Guide 1. Introduction 1.1 This policy has been developed by the South East London Clinical Commissioning
More informationCommunity DVT Service. Phase 3: Anticoagulation at DVT Treatment Centres
Community DVT Service Quick Reference Guide Phase - Anticoagulation Phase : Anticoagulation at DVT Treatment Centres If a Patient has had a positive Ultrasound Scan they attend one of the DVT Treatment
More informationMEDICINES RECONCILIATION GUIDELINE Document Reference
MEDICINES RECONCILIATION GUIDELINE Document Reference G358 Version Number 1.01 Author/Lead Job Title Jackie Stark Principle Pharmacist Clinical Services Date last reviewed, (this version) 29 November 2012
More informationVertebroplasty. Exceptional healthcare, personally delivered
Vertebroplasty Exceptional healthcare, personally delivered Your Doctor has requested that you have a vertebroplasty. We hope the following information will answer some of the questions you may have about
More informationCamden Clinical Commissioning Group Reporting Mechanism/Frequency Remotely/Quarterly
Universal Offer Service Anticoagulation - Warfarin Clinical Lead Dr Kevan Ritchie Commissioner Camden Clinical Commissioning Group Reporting Mechanism/Frequency Remotely/Quarterly Payment Frequency Quarterly
More informationClinical Check of Prescriptions in Ward Areas
Pharmacy Department Standard Operating Procedures SOP Title Clinical Check of Prescriptions in Ward Areas Author name and Gareth Price designation: Deputy Director of Pharmacy Clinical Services Pharmacy
More informationSUMMARY. Our progress in 2013/14. Eastbourne, Hailsham and Seaford Clinical Commissioning Group.
Eastbourne, Hailsham and Seaford Clinical Commissioning Group SUMMARY Our progress in 2013/14 www.eastbournehailshamandseafordccg.nhs.uk 1 Welcome NHS is a membership organisation made up of the 21 GP
More informationChemotherapy Practice Competencies. To be used in conjunction with Teesside University module:
Chemotherapy Practice Competencies To be used in conjunction with Teesside University module: AHH3088-N - Chemotherapy Enhancing Practice in Cancer Care School of Health & Social Care NAME. PLACE OF WORK
More informationPOLICY FOR the Assessment, Prevention and Treatment of Venous Thrombo-Embolism. Policy Reference: Version: 1 Status: Approved
POLICY FOR the Assessment, Prevention and Treatment of Venous Thrombo-Embolism Policy Reference: Version: 1 Status: Approved Type: Clinical Policy applies to : All SCH staff within relevant groups; community
More informationRevalidation Annual Report
Paper 31 14 Revalidation Annual Report 2013-14 Purpose of Document: To provide the Board with a report on the first year s experience with medical revalidation in Public Health Wales. Board/Committee to-
More informationNHS England Personal Medical Services (PMS) Contract Review update
DRAFT subject to change PAPER 06 NHS England Personal Medical (PMS) Contract Review update 23 February 2016 Author: William Cunningham-Davis 1 NHS England and the CCG s in South West have reviewed the
More informationSPONSORSHIP AND JOINT WORKING WITH THE PHARMACEUTICAL INDUSTRY
SPONSORSHIP AND JOINT WORKING WITH THE PHARMACEUTICAL INDUSTRY 1 SUMMARY This document sets out Haringey Clinical Commissioning Group policy and advice to employees on sponsorship and joint working with
More informationCity and Hackney Clinical Commissioning Group Prospectus May 2013
City and Hackney Clinical Commissioning Group Prospectus May 2013 Foreword We are excited to be finally live as a CCG, picking up our responsibilities as commissioners for the bulk of the NHS. The changeover
More information